Clinical Trial Update: A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update assesses the pharmacokinetics, safety, and tolerability of repeat oral doses of Darapladib in subjects with severe renal impa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• Darapladib (darapladib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Atherosclerosis | Phase 1 | Status: COMPLETED